Drug design strategies for Cushing’s syndrome

References

• Feelders RA, Newell-Price J, Pivonello R, et al. Advances in the medical treatment of Cushing’s syndrome. The Lancet Diabetes Endocrinol. 2018;S2213-S8587(18):30155–30164.
   Google Scholar
• Doyle NM, Doyle JF, Walter EJ. The life and work of Harvey Cushing 1869–1939: A pioneer of neurosurgery. J Intensive Care Soc. 2017;18:157–158.
   PubMedGoogle Scholar
• Nieman LK. Recent updates on the diagnosis and management of Cushing’s syndrome. Endocrinol Metab (Seoul, Korea). 2018;33:139–146.
   PubMedGoogle Scholar
• Pivonello R, Isidori AM, De Martino MC, et al. Complications of Cushing’s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4:611–629.
   PubMed Web of Science ®Google Scholar
• Pivonello R, De Martino MC, De Leo M, et al. Cushing’s disease: the burden of illness. Endocrine. 2017;56:10–18.
   PubMed Web of Science ®Google Scholar
• Newell-Price J. Pituitary gland: mortality in Cushing disease. Nat Rev Endocrinol. 2016;12:502–503.
   PubMed Web of Science ®Google Scholar
• Tritos NA, Biller BMK. Advances in medical therapies for Cushing’s syndrome. Discov Med. 2012;13:171–179.
   PubMed Web of Science ®Google Scholar
• Caimari F, Corcoy R, Webb SM. Cushing’s disease: major difficulties in diagnosis and management during pregnancy. Minerva Endocrinol. 2018;43:435–445.
   PubMedGoogle Scholar
• Ma L, Yin L, Hu Q. Therapeutic compounds for Cushing’s syndrome: a patent review (2012–2016). Expert Opin Ther Pat. 2016;26:1307–1323.
   PubMed Web of Science ®Google Scholar
• Zhu W, Chen Z, Li Q, et al. Inhibitors of 11β-Hydroxylase (CYP11B1) for treating diseases related to excess cortisol. Curr Med Chem. 2016;23:623–633.
   PubMed Web of Science ®Google Scholar
• Bernhardt R. The potential of targeting CYP11B. Expert Opin Ther Targets. 2016;20:923–934.
   PubMed Web of Science ®Google Scholar
• Borgers M, Van Den Bossche H, De Brabander M. The mechanism of action of the new antimycotic ketoconazole. Am J Med. 1983;74:2–8.
   PubMedGoogle Scholar
• Loose DS, Kan PB, Hirst MA, et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983;71:1495–1499.
   PubMed Web of Science ®Google Scholar
• Daniel E, Newell-Price JDC. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing’s syndrome. Eur J Endocrinol. 2015;172:R263–80.
   PubMed Web of Science ®Google Scholar
• Young J, Bertherat J, Vantyghem MC, et al. Hepatic safety of ketoconazole in Cushing’s syndrome: results of a compassionate use programme in France. Eur J Endocrinol. 2018;178:447–458.
   PubMed Web of Science ®Google Scholar
• Ceccato F, Zilio M, Barbot M, et al. Metyrapone treatment in Cushing’s syndrome: a real-life study. Endocrine. 2018;62:701–711.
   PubMed Web of Science ®Google Scholar
• Sonino N, Chow D, Levine LS, et al. Clinical response to metyrapone as indicated by measurement of mineralocorticoids and glucocorticoids in normal children. Clin Endocrinol (Oxf). 1981;14:31–39.
   PubMed Web of Science ®Google Scholar
• Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf). 1991;35:169–178.
   PubMed Web of Science ®Google Scholar
• Rotstein DM, Kertesz DJ, Walker KA, et al. Stereoisomers of ketoconazole: preparation and biological activity. J Med Chem. 1992;35:2818–2825.
   PubMed Web of Science ®Google Scholar
• Auchus RJ, Wu Y, Liu H-MP J. 2S,4R-ketoconazole is the relevant enantiomer of ketoconazole for cortisol synthesis inhibition: steroidogenic P450s inhibition involves multiple mechanisms. Endocr Rev. 2018;39,2(Suppl):SUN–410.
   Google Scholar
• Browne LJ, Gude C, Rodriguez H, et al. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. J Med Chem. 1991;34:725–736.
   PubMed Web of Science ®Google Scholar
• Azizi M, Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant. 2013;28:36–43.
   PubMed Web of Science ®Google Scholar
• Bertagna X, Pivonello R, Fleseriu M, et al. LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014;99:1375–1383.
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing’s disease. Pituitary. 2016;19:138–148.
   PubMed Web of Science ®Google Scholar
• Rainey WE. Adrenal zonation: clues from 11beta-hydroxylase and aldosterone synthase. Mol Cell Endocrinol. 1999;151:151–160.
   PubMed Web of Science ®Google Scholar
• Hattangady NG, Olala LO, Bollag WB, et al. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012;350:151–162.
   PubMed Web of Science ®Google Scholar
• Denner K, Doehmer J, Bernhardt R. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells. Endocr Res. 21:443–448.
   PubMed Web of Science ®Google Scholar
• Strushkevich N, Gilep AA, Shen L, et al. Structural insights into aldosterone synthase substrate specificity and targeted inhibition. Mol Endocrinol. 2013;27:315–324.
   PubMed Web of Science ®Google Scholar
• Rösler A, Leiberman E, Sack J, et al. Clinical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. Horm Res. 1982;16:133–141.
   PubMedGoogle Scholar
• White PC, Dupont J, New MI, et al. A mutation in CYP11B1 (Arg-448—-his) associated with steroid 11 beta-hydroxylase deficiency in Jews of Moroccan origin. J Clin Invest. 1991;87:1664–1667.
   PubMed Web of Science ®Google Scholar
• Hille UE, Zimmer C, Vock CA, et al. First selective CYP11B1 inhibitors for the treatment of Cortisol-Dependent Diseases. ACS Med Chem Lett. 2011;2:2–6.
   PubMed Web of Science ®Google Scholar
• Emmerich J, Hu Q, Hanke N, et al. Cushing’s syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type. J Med Chem. 2013;56:6022–6032.
   PubMed Web of Science ®Google Scholar
• Emmerich J, van Koppen CJ, Burkhart JL, et al. Lead optimization generates CYP11B1 inhibitors of pyridylmethyl isoxazole type with improved pharmacological profile for the treatment of Cushing’s disease. J Med Chem. 2017;60:5086–5098.
   PubMed Web of Science ®Google Scholar
• Ehmer PB, Bureik M, Bernhardt R, et al. Development of a test system for inhibitors of human aldosterone synthase (CYP11B2): screening in fission yeast and evaluation of selectivity in V79 cells. J Steroid Biochem Mol Biol. 2002;81:173–179.
   PubMed Web of Science ®Google Scholar
• Gobbi S, Hu Q, Zimmer C, et al. Drifting of heme-coordinating group in imidazolylmethylxanthones leading to improved selective inhibition of CYP11B1. Eur J Med Chem. 2017;139:60–67.
   PubMed Web of Science ®Google Scholar
• Papillon JPN, Adams CM, Hu Q-Y, et al. Structure-activity relationships, pharmacokinetics, and in vivo activity of CYP11B2 and CYP11B1 inhibitors. J Med Chem. 2015;58:4749–4770.
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Sasaki W, Onda Y, et al. Discovery of novel pyrazole-based selective aldosterone synthase (CYP11B2) Inhibitors: a new template to coordinate the heme-iron motif of CYP11B2. J Med Chem. 2018;61:5594–5608.
   PubMed Web of Science ®Google Scholar
• Hoyt SB, Taylor J, London C, et al. Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension. Bioorg Med Chem Lett. 2017;27:2384–2388.
   PubMed Web of Science ®Google Scholar
• Meyers K, Cogan DA, Burke J, et al. Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity. Bioorg Med Chem Lett. 2018;28:979–984.
   PubMed Web of Science ®Google Scholar
• Pratt WB, Morishima Y, Murphy M, et al. Chaperoning of glucocorticoid receptors. Handb Exp Pharmacol. 2006;172:111–138.
   PubMedGoogle Scholar
• Bodwell JE, Webster JC, Jewell CM, et al. Glucocorticoid receptor phosphorylation: overview, function and cell cycle-dependence. J Steroid Biochem Mol Biol. 1998;65:91–99.
   PubMed Web of Science ®Google Scholar
• Ratman D, Vanden Berghe W, Dejager L, et al. How glucocorticoid receptors modulate the activity of other transcription factors: a scope beyond tethering. Mol Cell Endocrinol. 2013;380:41–54.
   PubMed Web of Science ®Google Scholar
• Ripa L, Edman K, Dearman M, et al. Discovery of a novel oral glucocorticoid receptor modulator (AZD9567) with improved side effect profile. J Med Chem. 2018;61:1785–1799.
   PubMed Web of Science ®Google Scholar
• Biggadike K, Bledsoe RK, Coe DM, et al. Design and x-ray crystal structures of high-potency nonsteroidal glucocorticoid agonists exploiting a novel binding site on the receptor. Proc Natl Acad Sci U S A. 2009;106:18114–18119.
   PubMed Web of Science ®Google Scholar
• Hemmerling M, Nilsson S, Edman K, et al. Selective nonsteroidal glucocorticoid receptor modulators for the inhaled treatment of pulmonary diseases. J Med Chem. 2017;60:8591–8605.
   PubMed Web of Science ®Google Scholar
• He Y, Yi W, Suino-Powell K, et al. Structures and mechanism for the design of highly potent glucocorticoids. Cell Res. 2014;24:713–726.
   PubMed Web of Science ®Google Scholar
• Bledsoe RK, Montana VG, Stanley TB, et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell. 2002;110:93–105.
   PubMed Web of Science ®Google Scholar
• Kauppi B, Jakob C, Färnegårdh M, et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem. 2003;278:22748–22754.
   PubMed Web of Science ®Google Scholar
• Schoch GA, D’Arcy B, Stihle M, et al. Molecular switch in the glucocorticoid receptor: active and passive antagonist conformations. J Mol Biol. 2010;395:568–577.
   PubMed Web of Science ®Google Scholar
• Bledsoe RK, Stewart EL, Pearce KH. Structure and function of the glucocorticoid receptor ligand binding domain. Vitam Horm. 2004;68:49–91.
   PubMed Web of Science ®Google Scholar
• Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab. 1985;61:536–540.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Thalabard JC, De Plunkett TL, et al. The use of the antiprogestin RU486 (mifepristone) as an abortifacient in early pregnancy–clinical and pathological findings; predictive factors for efficacy. Contraception. 1990;41:221–243.
   PubMed Web of Science ®Google Scholar
• Carmichael JD, Fleseriu M. Mifepristone: is there a place in the treatment of Cushing’s disease? Endocrine. 2013;44:20–32.
   PubMed Web of Science ®Google Scholar
• Zhang S, Jonklaas J, Danielsen M. The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007;72:600–608.
   PubMed Web of Science ®Google Scholar
• Hu X, Du S, Tunca C, et al. The antagonists but not partial agonists of glucocorticoid receptor ligands show substantial side effect dissociation. Endocrinology. 2011;152:3123–3134.
   PubMed Web of Science ®Google Scholar
• Robertson JF, Willsher PC, Winterbottom L, et al. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999;35:214–218.
   PubMed Web of Science ®Google Scholar
• Teutsch G, Gaillard-Moguilewsky M, Lemoine G, et al. Design of ligands for the glucocorticoid and progestin receptors. Biochem Soc Trans. 1991;19:901–908.
   PubMed Web of Science ®Google Scholar
• Miner JN, Tyree C, Hu J, et al. A nonsteroidal glucocorticoid receptor antagonist. Mol Endocrinol. 2003;17:117–127.
   PubMed Web of Science ®Google Scholar
• Beaudry JL, Dunford EC, Teich T, et al. Effects of selective and non-selective glucocorticoid receptor II antagonists on rapid-onset diabetes in young rats. PLoS One. 2014;9:e91248.
   PubMed Web of Science ®Google Scholar
• Simmons LR, Molyneaux L, Yue DK, et al. Steroid-induced diabetes: is it just unmasking of type 2 diabetes? ISRN Endocrinol. 2012;2012:910905.
   PubMedGoogle Scholar
• Morgan BP, Swick AG, Hargrove DM, et al. Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002;45:2417–2424.
   PubMed Web of Science ®Google Scholar
• Mohler ML, He Y, Wu Z, et al. Non-steroidal glucocorticoid receptor antagonists: the race to replace RU-486 for anti-glucocorticoid therapy. Expert Opin Ther Pat. 2007;17:59–81.
   PubMed Web of Science ®Google Scholar
• Link JT, Sorensen B, Patel J, et al. Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators. J Med Chem. 2005;48:5295–5304.
   PubMed Web of Science ®Google Scholar
• Kroon J, Koorneef LL, Van Den Heuvel JK, et al. Selective glucocorticoid receptor antagonist CORT125281 activates brown adipose tissue and alters lipid distribution in male mice. Endocrinology. 2018;159:535–546.
   PubMed Web of Science ®Google Scholar
• Brixius-Anderko S, Scott EE. Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design. J Biol Chem. 2018.
   PubMedGoogle Scholar
• Rastinejad F, Ollendorff V, Polikarpov I. Nuclear receptor full-length architectures: confronting myth and illusion with high resolution. Trends Biochem Sci. 2015;40:16–24.
   PubMed Web of Science ®Google Scholar
• Miller WL. Steroidogenesis: unanswered questions. Trends Endocrinol Metab. 2017;28:771–793.
   PubMed Web of Science ®Google Scholar
• Schiffer L, Anderko S, Hannemann F, et al. The CYP11B subfamily. J Steroid Biochem Mol Biol. 2015;151:38–51.
   PubMed Web of Science ®Google Scholar
• Gilep AA, Sushko TA, Usanov SA. At the crossroads of steroid hormone biosynthesis: the role, substrate specificity and evolutionary development of CYP17. Biochim Biophys Acta. Acta - Proteins Proteomics. 2011;1814:200–209.
   PubMed Web of Science ®Google Scholar